Intra-Cellular Therapies Management
Management criteria checks 2/4
Intra-Cellular Therapies' CEO is Sharon Mates, appointed in May 2002, has a tenure of 22.33 years. total yearly compensation is $10.09M, comprised of 8.8% salary and 91.2% bonuses, including company stock and options. directly owns 1.01% of the company’s shares, worth R$433.64M. The average tenure of the management team and the board of directors is 6 years and 10.7 years respectively.
Key information
Sharon Mates
Chief executive officer
US$10.1m
Total compensation
| CEO salary percentage | 8.8% |
| CEO tenure | 22.3yrs |
| CEO ownership | 1.0% |
| Management average tenure | 6yrs |
| Board average tenure | 10.7yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$84m |
| Mar 31 2024 | n/a | n/a | -US$111m |
| Dec 31 2023 | US$10m | US$892k | -US$140m |
| Sep 30 2023 | n/a | n/a | -US$155m |
| Jun 30 2023 | n/a | n/a | -US$184m |
| Mar 31 2023 | n/a | n/a | -US$228m |
| Dec 31 2022 | US$9m | US$849k | -US$256m |
| Sep 30 2022 | n/a | n/a | -US$298m |
| Jun 30 2022 | n/a | n/a | -US$321m |
| Mar 31 2022 | n/a | n/a | -US$304m |
| Dec 31 2021 | US$7m | US$794k | -US$284m |
| Sep 30 2021 | n/a | n/a | -US$259m |
| Jun 30 2021 | n/a | n/a | -US$237m |
| Mar 31 2021 | n/a | n/a | -US$232m |
| Dec 31 2020 | US$5m | US$767k | -US$227m |
| Sep 30 2020 | n/a | n/a | -US$207m |
| Jun 30 2020 | n/a | n/a | -US$187m |
| Mar 31 2020 | n/a | n/a | -US$160m |
| Dec 31 2019 | US$5m | US$745k | -US$148m |
| Sep 30 2019 | n/a | n/a | -US$148m |
| Jun 30 2019 | n/a | n/a | -US$155m |
| Mar 31 2019 | n/a | n/a | -US$154m |
| Dec 31 2018 | US$4m | US$723k | -US$155m |
| Sep 30 2018 | n/a | n/a | -US$145m |
| Jun 30 2018 | n/a | n/a | -US$126m |
| Mar 31 2018 | n/a | n/a | -US$106m |
| Dec 31 2017 | US$5m | US$702k | -US$98m |
Compensation vs Market: Sharon's total compensation ($USD10.09M) is above average for companies of similar size in the BR market ($USD2.84M).
Compensation vs Earnings: Sharon's compensation has increased whilst the company is unprofitable.
CEO
Sharon Mates (71 yo)
22.3yrs
Tenure
US$10,086,413
Compensation
Dr. Sharon Mates, Ph.D. co-founded Intra-Cellular Therapies, Inc. (a/k/a ITI) in May 2002 and was its President until March 19, 2024. She has been Chairman and Chief Executive Officer of Intra-Cellular The...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 22.3yrs | US$10.09m | 1.01% $ 454.8m | |
| President | less than a year | US$3.53m | 0% $ 0 | |
| Executive VP & Chief Medical Officer | 6.1yrs | US$3.51m | 0.019% $ 8.4m | |
| EVP & Chief Commercial Officer | 5.9yrs | US$3.54m | 0.028% $ 12.6m | |
| Senior VP & Chief Scientific Officer | 8.8yrs | US$2.13m | no data | |
| Vice President of Corporate Communications & Investor Relations | 10.5yrs | US$1.38m | no data | |
| Senior VP & Chief Compliance Officer | 5.2yrs | no data | no data | |
| Senior Vice President | no data | no data | no data | |
| Senior VP & Head of Regulatory Affairs | 6yrs | no data | no data | |
| Senior VP of Market Access | 5.5yrs | no data | no data | |
| Senior VP & Head of Clinical Development | 2.4yrs | no data | no data |
6.0yrs
Average Tenure
61yo
Average Age
Experienced Management: I2TC34's management team is seasoned and experienced (6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 11.1yrs | US$10.09m | 1.01% $ 454.8m | |
| Independent Director | 10.7yrs | US$470.51k | 0.11% $ 49.7m | |
| Lead Independent Director | 10.7yrs | US$507.58k | 0.011% $ 4.8m | |
| Independent Director | 11.1yrs | US$473.34k | 0.039% $ 17.5m | |
| Chairman of Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Independent Director | 2.4yrs | US$461.30k | 0.0015% $ 664.5k |
10.7yrs
Average Tenure
71yo
Average Age
Experienced Board: I2TC34's board of directors are seasoned and experienced ( 10.7 years average tenure).